704 related articles for article (PubMed ID: 32478895)
21. Resource-sparing curative-intent hypofractionated-accelerated radiotherapy in head and neck cancer: More relevant than ever before in the COVID era.
Gupta T; Ghosh-Laskar S; Agarwal JP
Oral Oncol; 2020 Dec; 111():105045. PubMed ID: 33091846
[TBL] [Abstract][Full Text] [Related]
22. Impact of HPV infection on the clinical outcome of p-CAIR trial in head and neck cancer.
Snietura M; Piglowski W; Jaworska M; Mucha-Malecka A; Wozniak G; Lange D; Suwinski R
Eur Arch Otorhinolaryngol; 2011 May; 268(5):721-6. PubMed ID: 20938670
[TBL] [Abstract][Full Text] [Related]
23. Human papilloma virus status evaluation and survival description in selected oropharyngeal and laryngeal squamous cell carcinoma patients from Hungary.
Reka Fejer E; Abram Z; Zs Egyed J; Voidazan S; Toth E; Szentirmay Z; Kasler M
J BUON; 2016; 21(1):168-74. PubMed ID: 27061545
[TBL] [Abstract][Full Text] [Related]
24. nab-Paclitaxel-based induction chemotherapy followed by cisplatin and radiation therapy for human papillomavirus-unrelated head and neck squamous-cell carcinoma.
Johnson KCC; Ley J; Oppelt P; Lu J; Gay HA; Daly M; Jackson R; Rich J; Pipkorn P; Paniello RC; Zevallos J; Thorstad W; Adkins DR
Med Oncol; 2019 Oct; 36(11):93. PubMed ID: 31595355
[TBL] [Abstract][Full Text] [Related]
25. Phase II Trial of De-Intensified Chemoradiotherapy for Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma.
Chera BS; Amdur RJ; Green R; Shen C; Gupta G; Tan X; Knowles M; Fried D; Hayes N; Weiss J; Grilley-Olson J; Patel S; Zanation A; Hackman T; Zevallos J; Blumberg J; Patel S; Kasibhatla M; Sheets N; Weissler M; Yarbrough W; Mendenhall W
J Clin Oncol; 2019 Oct; 37(29):2661-2669. PubMed ID: 31411949
[TBL] [Abstract][Full Text] [Related]
26. A phase II randomized trial comparing neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in advanced squamous cell carcinoma of the pharynx or larynx.
Huang PW; Lin CY; Hsieh CH; Hsu CL; Fan KH; Huang SF; Liao CT; Ng SK; Yen TC; Chang JT; Wang HM
Biomed J; 2018 Apr; 41(2):129-136. PubMed ID: 29866601
[TBL] [Abstract][Full Text] [Related]
27. Value of intensity-modulated radiotherapy in Stage IV head-and-neck squamous cell carcinoma.
Dirix P; Nuyts S
Int J Radiat Oncol Biol Phys; 2010 Dec; 78(5):1373-80. PubMed ID: 20362402
[TBL] [Abstract][Full Text] [Related]
28. Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab.
Rosenthal DI; Harari PM; Giralt J; Bell D; Raben D; Liu J; Schulten J; Ang KK; Bonner JA
J Clin Oncol; 2016 Apr; 34(12):1300-8. PubMed ID: 26712222
[TBL] [Abstract][Full Text] [Related]
29. Concurrent weekly cisplatin and simultaneous integrated boost intensity-modulated radiotherapy of locally advanced squamous cell carcinoma of the head and neck.
Dubinský P; Jeremic B; Švajdová M; Barilíková G; Matula P; Nadzonová D; Vojtek V
Klin Onkol; 2022; 35(4):307-314. PubMed ID: 35989088
[TBL] [Abstract][Full Text] [Related]
30. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis.
Iyer NG; Tan DS; Tan VK; Wang W; Hwang J; Tan NC; Sivanandan R; Tan HK; Lim WT; Ang MK; Wee J; Soo KC; Tan EH
Cancer; 2015 May; 121(10):1599-607. PubMed ID: 25639864
[TBL] [Abstract][Full Text] [Related]
31. Costs of Definitive Chemoradiation, Surgery, and Adjuvant Radiation Versus De-Escalated Adjuvant Radiation per MC1273 in HPV+ Cancer of the Oropharynx.
Waddle MR; Ma DJ; Visscher SL; Borah BJ; May JM; Price KA; Moore EJ; Patel SH; Hinni ML; Chintakuntlawar AV; Garcia JJ; Graner DE; Neben-Wittich MA; Garces YI; Hallemeier CL; Price DL; Kasperbauer JL; Janus JR; Foote RL; Miller RC
Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):396-402. PubMed ID: 33359567
[TBL] [Abstract][Full Text] [Related]
32. Locoregional and distant recurrence for HPV-associated oropharyngeal cancer using AJCC 8 staging.
Contrera KJ; Smile TD; Mahomva C; Wei W; Adelstein DJ; Broughman JR; Burkey BB; Geiger JL; Joshi NP; Ku JA; Lamarre ED; Lorenz RR; Prendes BL; Scharpf J; Schwartzman LM; Woody NM; Xiong D; Koyfman SA
Oral Oncol; 2020 Dec; 111():105030. PubMed ID: 33038751
[TBL] [Abstract][Full Text] [Related]
33. Long-term outcome of seropositive HIV patients with head and neck squamous cell carcinoma treated with radiation therapy and chemotherapy.
Mourad WF; Hu KS; Shasha D; Concert C; Ishihara D; Lin W; Gamez ME; Lukens JN; Shourbaji RA; Ryniak M; Li Z; Culliney BE; Khorsandi AS; Tran T; Jacobson A; Manolidis S; Schantz S; Urken M; Persky MS; Harrison LB
Anticancer Res; 2013 Dec; 33(12):5511-6. PubMed ID: 24324090
[TBL] [Abstract][Full Text] [Related]
34. Impact of chemotherapy regimen on treatment outcomes in patients with HPV-associated oropharyngeal cancer with T4 disease treated with definitive concurrent chemoradiation.
Bhattasali O; Ryoo JJ; Thompson LDR; Abdalla IA; Chen J; Iganej S
Oral Oncol; 2019 Aug; 95():74-78. PubMed ID: 31345397
[TBL] [Abstract][Full Text] [Related]
35. DAHANCA 28: A phase I/II feasibility study of hyperfractionated, accelerated radiotherapy with concomitant cisplatin and nimorazole (HART-CN) for patients with locally advanced, HPV/p16-negative squamous cell carcinoma of the oropharynx, hypopharynx, larynx and oral cavity.
Saksø M; Jensen K; Andersen M; Hansen CR; Eriksen JG; Overgaard J
Radiother Oncol; 2020 Jul; 148():65-72. PubMed ID: 32335364
[TBL] [Abstract][Full Text] [Related]
36. Impact of clinical complete response on treatment outcomes in patients with locally advanced HPV-negative oropharyngeal squamous cell carcinoma.
De Felice F; Musio D; Abate G; Moscarelli E; Bulzonetti N; Tombolini V
J Cancer Res Clin Oncol; 2020 Feb; 146(2):477-483. PubMed ID: 31686249
[TBL] [Abstract][Full Text] [Related]
37. Hypopharyngeal squamous cell carcinoma: Three-dimensional or Intensity-modulated radiotherapy? A single institution's experience.
Katsoulakis E; Riaz N; Hu M; Morris L; Sherman E; McBride S; Lee N
Laryngoscope; 2016 Mar; 126(3):620-6. PubMed ID: 26597398
[TBL] [Abstract][Full Text] [Related]
38. Practice patterns and outcomes following radiation dose de-escalation for oropharyngeal cancer.
White R; Abel S; Hasan S; Verma V; Greenberg L; Colonias A; Wegner RE
Laryngoscope; 2020 Apr; 130(4):E171-E176. PubMed ID: 31120601
[TBL] [Abstract][Full Text] [Related]
39. Effect of definitive hypo-fractionated radiotherapy concurrent with weekly cisplatin in locally advanced squamous cell carcinoma of the head and neck.
Abdelhafiz N; Mahmoud D; Gad M; Essa H; Morsy A
J Med Life; 2023 May; 16(5):743-750. PubMed ID: 37520484
[TBL] [Abstract][Full Text] [Related]
40. EGFR overexpression increases radiotherapy response in HPV-positive head and neck cancer through inhibition of DNA damage repair and HPV E6 downregulation.
Alsahafi EN; Thavaraj S; Sarvestani N; Novoplansky O; Elkabets M; Ayaz B; Tavassoli M; Legends MF
Cancer Lett; 2021 Feb; 498():80-97. PubMed ID: 33137407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
